Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander G G Turpie

Showing results (51-60 of 177) with videos related to

Pageof 18
Sort By:
Journal of the Southern Orthopaedic Association|February 25, 2003
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgeryAlexander G G Turpie, Bengt I Eriksson, Michael R Lassen, et al.
Journal of the American College of Cardiology|April 12, 2008
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) studyMichael R Lassen, Ola Dahl, Patrick Mismetti, et al.
Current Opinion in Pulmonary Medicine|August 13, 2002
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolismKenneth A Bauer, Bengt I Eriksson, Michael R Lassen, et al.
Lancet (London, England)|June 7, 2002
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonMichael Rud Lassen, Kenneth A Bauer, Bengt I Eriksson, et al.
Lancet (London, England)|June 7, 2002
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.
Current Opinion in Hematology|August 13, 2003
Fondaparinux, the first selective factor Xa inhibitorAlexander G G Turpie, Bengt I Eriksson, Michael R Lassen, et al.
Journal of the Southern Orthopaedic Association|February 25, 2003
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialistKenneth A Bauer, Bengt I Eriksson, Michael R Lassen, et al.
Archives of Internal Medicine|August 28, 2002
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.
Lancet (London, England)|November 15, 2003
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgeryAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.
Journal of Thrombosis and Thrombolysis|June 9, 2018
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolismCraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Pageof 18

Showing results (51-60 of 177) with videos related to

Sort By:
Pageof 18
Journal of the Southern Orthopaedic Association|February 25, 2003
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgeryAlexander G G Turpie, Bengt I Eriksson, Michael R Lassen, et al.
Journal of the American College of Cardiology|April 12, 2008
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) studyMichael R Lassen, Ola Dahl, Patrick Mismetti, et al.
Current Opinion in Pulmonary Medicine|August 13, 2002
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolismKenneth A Bauer, Bengt I Eriksson, Michael R Lassen, et al.
Lancet (London, England)|June 7, 2002
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonMichael Rud Lassen, Kenneth A Bauer, Bengt I Eriksson, et al.
Lancet (London, England)|June 7, 2002
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.
Current Opinion in Hematology|August 13, 2003
Fondaparinux, the first selective factor Xa inhibitorAlexander G G Turpie, Bengt I Eriksson, Michael R Lassen, et al.
Journal of the Southern Orthopaedic Association|February 25, 2003
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialistKenneth A Bauer, Bengt I Eriksson, Michael R Lassen, et al.
Archives of Internal Medicine|August 28, 2002
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.
Lancet (London, England)|November 15, 2003
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgeryAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.
Journal of Thrombosis and Thrombolysis|June 9, 2018
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolismCraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Pageof 18